Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuRIDICE: Haloperidol for Delirium in ICU Patients
NCT03628391Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Haloperidol with Placebo (2 arms). Primary endpoint: Delirium- and coma-free days at 14 days. Started Feb 2018; status: terminated.
02
Drugs
haloperidol
03
Conditions
delirium
Beyond the preview
Go deeper on NCT03628391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03628391.